



Eurofins launches cutting-edge biomarker discovery and bioanalytical services laboratory in Aurora, Colorado

Brussels/ Nantes, May 9, 2007

Eurofins announced today that their newly-established laboratory in the Fitzsimons Biotech Park in Aurora, Colorado is now fully operational and, operating under the Eurofins | Medinet brand, extends the Eurofins network of central laboratories in Europe, Asia and the US to provide services for our customers in the pharmaceutical clinical trial and drug development sector.

The Eurofins | Medinet laboratory in Aurora provides innovative mass spectrometry-based technologies for the development, validation and measurement of biomarkers and biomarker strategies. This includes targeted and non-targeted biochemical profiling (metabolomics) and protein profiling (proteomics). In addition, the laboratory offers the development and validation of assays for the quantification of endogenous compounds, drugs and their metabolites based on highly sensitive and specific mass spectrometry assays as well as bioanalytical services for all stages of drug development. The Aurora laboratory is strategically located next to the new University of Colorado Health Sciences Center campus and has strong collaborative links with university researchers. Eurofins | Medinet in Aurora is led by General Manager Professor Uwe Christians, who is supported by a dedicated team that has a long and successful track record in these fields.

"The development of biomarkers will be critical for developing better and safer drugs, as well as more sensitive and specific clinical diagnostics" said Dr. Arnold Verbeek, CEO at Eurofins | Medinet. "The global biomarker market is quickly expanding. We are combining cutting-edge expertise, technology, research, development and validation services in a regulatory compliant environment, that makes Eurofins | Medinet a unique world-wide resource and a valuable partner for the pharmaceutical and biotech industry."

Eurofins | Medinet provides specialized testing in microbiology, bioanalysis, genomics, pharmacokinetics, general safety testing and biomarker development using its fully accredited central laboratories in the Netherlands, USA (two labs), France and Singapore with additional standardised partner laboratories in South Africa, India, China, Japan, and Australia.

For further information please contact your Eurofins laboratory or contact directly:

Professor Uwe Christians, MD, PhD

General Manager

Eurofins | Medinet

Tel.: +1 720 859 4190

Email: uwe.christians@eurofinsmedinet.com

or

Investor Relations

Tel.: +32-2-766 16 20

Email: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With over 5,000 staff in more than 70 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext exchange in Paris (ISIN FR0000038259) and the Frankfurt (WKN 910251) Stock Exchange (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.